- Home
- XENE
as 06-20-2025 4:00pm EST
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
| Founded: | 1996 | Country: | Canada |
| Employees: | N/A | City: | BURNABY |
| Market Cap: | 2.3B | IPO Year: | 2014 |
| Target Price: | $54.82 | AVG Volume (30 days): | 977.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.22 | EPS Growth: | N/A |
| 52 Week Low/High: | $26.74 - $46.00 | Next Earning Date: | 08-07-2025 |
| Revenue: | $7,500,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 253.71% |
Stock Insider Trading Activity of Xenon Pharmaceuticals Inc. (XENE)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| GANNON STEVEN | XENE | Director | Jun 5 '25 | Sell | $30.48 | 3 | $91.44 | 7,141 |
Latest Xenon Pharmaceuticals Inc. News
XENE Breaking Stock News: Dive into XENE Ticker-Specific Updates for Smart Investing
MT Newswires
8 days ago
RBC Raises Price Target on Xenon Pharmaceuticals to $57 From $55, Keeps Outperform, Speculative Risk
Zacks
10 days ago
Xenon Pharmaceuticals (XENE) Up 8.7% Since Last Earnings Report: Can It Continue?
GlobeNewswire
18 days ago
Xenon to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
GlobeNewswire
22 days ago
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
a month ago
Xenon to Present at the 2025 RBC Capital Markets Global Healthcare Conference
Insider Monkey
a month ago
Why Xenon Pharmaceuticals Inc. (XENE) Declined on Tuesday
Zacks
a month ago
Xenon Q1 Loss Narrower Than Expected, Pipeline Development in Focus
MT Newswires
a month ago
RBC Adjusts Price Target on Xenon Pharmaceuticals to $55 From $58, Maintains Outperform Speculative Risk Rating
Compare XENE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "XENE Xenon Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.